Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 10/20 | 0.42 |
| ▸ | KHK | P50053 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.31 |
| ▸ | SORD | Q00796 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21713083 | 1.00 | KLKB1 (0.42) | KLKB1KHKMEN1KMT2APDE10A | |
| SCHEMBL21713082 | 1.00 | KLKB1 (0.42) | KLKB1KHKMEN1KMT2APDE10A | |
| SCHEMBL21736651 | 0.87 | KLKB1 (0.41) | KLKB1MEN1KMT2APDE10ASORD | |
| SCHEMBL21747132 | 0.87 | KLKB1 (0.41) | KLKB1MEN1KMT2APDE10ASORD | |
| SCHEMBL22134233 | 0.87 | KLKB1 (0.41) | KLKB1MEN1KMT2APDE10ASORD | |
| SCHEMBL23843145 | 0.83 | KLKB1 (0.35) | KLKB1MEN1KMT2ASORD | |
| SCHEMBL21713053 | 0.82 | KLKB1 (0.45) | KLKB1 | |
| SCHEMBL30140714 | 0.82 | KLKB1 (0.45) | KLKB1 | |
| SCHEMBL21713019 | 0.81 | KLKB1 (0.38) | KLKB1KHKPDE10A | |
| SCHEMBL21713020 | 0.81 | KLKB1 (0.38) | KLKB1KHKPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885KHK 31/4885MEN1 1059/4885 |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885KHK 31/4885MEN1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.